192 related articles for article (PubMed ID: 34456724)
1. The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy.
Xoxi E; Facey KM; Cicchetti A
Front Pharmacol; 2021; 12():699466. PubMed ID: 34456724
[TBL] [Abstract][Full Text] [Related]
2. Value assessment of medicinal products by the Italian Medicines Agency (AIFA) and French National Authority for Health (HAS): Similarities and discrepancies.
Xoxi E; Di Bidino R; Leone S; Aiello A; Prada M
Front Med Technol; 2022; 4():917151. PubMed ID: 36134249
[TBL] [Abstract][Full Text] [Related]
3. Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries.
Morel T; Arickx F; Befrits G; Siviero P; van der Meijden C; Xoxi E; Simoens S
Orphanet J Rare Dis; 2013 Dec; 8():198. PubMed ID: 24365263
[TBL] [Abstract][Full Text] [Related]
4. MONITORING REGISTRIES AT ITALIAN MEDICINES AGENCY: FOSTERING ACCESS, GUARANTEEING SUSTAINABILITY.
Montilla S; Xoxi E; Russo P; Cicchetti A; Pani L
Int J Technol Assess Health Care; 2015 Jan; 31(4):210-3. PubMed ID: 26646859
[TBL] [Abstract][Full Text] [Related]
5. [EMA approval procedures and assessment of innovation by AIFA: a cross sectional analysis.].
Lasala R
Recenti Prog Med; 2021 Apr; 112(4):273-284. PubMed ID: 33877088
[TBL] [Abstract][Full Text] [Related]
6. A Proposal for Value-Based Managed Entry Agreements in an Environment of Technological Change and Economic Challenge for Publicly Funded Healthcare Systems.
Xoxi E; Rumi F; Kanavos P; Dauben HP; Gutierrez-Ibarluzea I; Wong O; Rasi G; Cicchetti A
Front Med Technol; 2022; 4():888404. PubMed ID: 35782579
[TBL] [Abstract][Full Text] [Related]
7. Recovery of suspended reimbursements of high-cost drugs subjected to monitoring registries and negotiated agreements (MEAs): a tool for governance and clinical appropriateness in the Italian reality.
Capuozzo M; Celotto V; Zovi A; Langella R; Ferrara F
Eur J Health Econ; 2024 Feb; 25(1):1-5. PubMed ID: 37878195
[TBL] [Abstract][Full Text] [Related]
8. Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel.
Facey KM; Espin J; Kent E; Link A; Nicod E; O'Leary A; Xoxi E; van de Vijver I; Zaremba A; Benisheva T; Vagoras A; Upadhyaya S
Pharmacoeconomics; 2021 Sep; 39(9):1021-1044. PubMed ID: 34231135
[TBL] [Abstract][Full Text] [Related]
9. Orphan Medicinal Products for the Treatment of Pancreatic Cancer: Lessons Learned From Two Decades of Orphan Designation.
Mulder J; van Rossum T; Mariz S; Magrelli A; de Boer A; Pasmooij AMG; Stoyanova-Beninska V
Front Oncol; 2021; 11():809035. PubMed ID: 34988030
[TBL] [Abstract][Full Text] [Related]
10. Financial Outcomes of Managed Entry Agreements for Pharmaceuticals in Italy.
Trotta F; Guerrizio MA; Di Filippo A; Cangini A
JAMA Health Forum; 2023 Dec; 4(12):e234611. PubMed ID: 38153808
[TBL] [Abstract][Full Text] [Related]
11. Using GRADE methodology to assess innovation of new medicinal products in Italy.
Fortinguerra F; Tafuri G; Trotta F; Addis A
Br J Clin Pharmacol; 2020 Jan; 86(1):93-105. PubMed ID: 31656055
[TBL] [Abstract][Full Text] [Related]
12. CHARACTERISTICS OF MANAGED ENTRY AGREEMENTS IN AUSTRALIA.
Robinson MF; Mihalopoulos C; Merlin T; Roughead E
Int J Technol Assess Health Care; 2018 Jan; 34(1):46-55. PubMed ID: 29277174
[TBL] [Abstract][Full Text] [Related]
13. Independent Registries Are Cost-Effective Tools to Provide Mandatory Postauthorization Surveillance for Orphan Medicinal Products.
Sirrs SM; Arthus MF; Bichet DG; Rockman-Greenberg C; LeMoine K; Morel CF; Lachmann R; Lynd LD; Wasim S; West ML; Hollak C
Value Health; 2021 Feb; 24(2):268-273. PubMed ID: 33518033
[TBL] [Abstract][Full Text] [Related]
14. HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries.
Nicod E; Annemans L; Bucsics A; Lee A; Upadhyaya S; Facey K
Health Policy; 2019 Feb; 123(2):140-151. PubMed ID: 28400128
[TBL] [Abstract][Full Text] [Related]
15. Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden.
Ferrario A; Kanavos P
Soc Sci Med; 2015 Jan; 124():39-47. PubMed ID: 25461860
[TBL] [Abstract][Full Text] [Related]
16. Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis.
Vreman RA; Broekhoff TF; Leufkens HG; Mantel-Teeuwisse AK; Goettsch WG
Int J Environ Res Public Health; 2020 Nov; 17(22):. PubMed ID: 33182732
[TBL] [Abstract][Full Text] [Related]
17. Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries.
Efthymiadou O; Kanavos P
BMC Health Serv Res; 2022 Aug; 22(1):1066. PubMed ID: 35987627
[TBL] [Abstract][Full Text] [Related]
18. Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?
Jommi C; Addis A; Martini N; Nicod E; Pani M; Scopinaro A; Vogler S
Glob Reg Health Technol Assess; 2021; 8():114-119. PubMed ID: 36627869
[TBL] [Abstract][Full Text] [Related]
19. Contribution of patient registries to regulatory decision making on rare diseases medicinal products in Europe.
Jonker CJ; Bakker E; Kurz X; Plueschke K
Front Pharmacol; 2022; 13():924648. PubMed ID: 35991868
[TBL] [Abstract][Full Text] [Related]
20. [Innovative medicinal products: the new criteria of the Italian Medicines Agency.].
Mammarella F; Tafuri G
Recenti Prog Med; 2018 May; 109(5):261-262. PubMed ID: 29771247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]